|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUC = 0.74;P < .001), and might potentially be used as biomarkers for the identification of MGUS and MM patients, who are candidates for monitoring pre-symptomatic organ damage related to AL amyloidosis.
|
30542145 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We present the results of a completed phase I trial of single-agent lorvotuzumab mertansine, a unique antibody-drug conjugate targeting CD56, which is frequently expressed in MM.
|
30340993 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
|
29920491 |
2019 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Certain immunophenotypes in multiple myeloma (MM), including CD56 and CD117, have been reported to be associated with overall survival (OS).
|
30344721 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CPCs were immuno-phenotyped using a CD38/CD56/CD45 panel and identified in 78% of patients with monoclonal gammopathy of undetermined significance (MGUS), all patients with smouldering and symptomatic multiple myeloma (MM), and none in the controls.
|
29372735 |
2018 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with AL exhibited an increased cluster of differentiation (CD)19 expression compared with patients with MM, 4.5% (0.1-80.9%) vs. 1.6% (0.1-33.6%; P<0.001) and reduced CD138, with 90.8% (30.4-99.9%) vs. 95.0% (40.7-100%; P=0.006) and CD56, with 61.0% (1.5-99.2%) vs. 98.3% (0.1-100%; P<0.001) expression in malignant PCs.
|
28454452 |
2017 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study involved 46 patients with MM, and analyzed the prognostic significance of the expression of cluster of differentiation (CD)45, CD56 and mature plasma cell (MPC)-1, and other factors including the International Staging System (ISS) stage, age, gender, the immunoglobulin subtype and the treatment line number prior to bortezomib treatment.
|
28521480 |
2017 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The t(11;14) MM group was associated with a significantly higher positive rate of B-lineage associated antigens CD20 and CD79a as well as the lack of CD56 expression. t(11;14) was less likely to be accompanied by 13q14 deletion than 13q14 deletion frequency in non-t(11;14) population (p=0.026), and fewer patients displaying t(11;14) were identified as belonging to the high-risk cytogenetic group due to the extremely low incidence of t(4;14) and t(14;16).
|
23927993 |
2013 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed 102 cases of plasma cell neoplasm by flow cytometric immunophenotyping for expression of CD56 and CD117 and correlated the results with immunohistochemical and cytogenetic findings.
|
22423624 |
2012 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasma cell myelomas with t(11;14)(q13;q32) were frequently CD20(+) (46.4%) and CD56(-) (53.8%) and had a nonhyperdiploid karyotype (97.6%) with frequent 13q deletion (33.3%).Of 42 cases, 19 (45.2%) expressed CD23.
|
21724429 |
2011 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).
|
20096010 |
2010 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the contrary, over-expression of SOX4 in the CD56(-) myeloma cell line could induce the CD56 expression.
|
20049565 |
2010 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings propose four potential activators of the CD56 promoter and for CD56 to be involved in proliferation and anti-apoptosis, leading to disease progression in MM.
|
19235015 |
2009 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data indicates that p53 nuclear expression but not CD56 expression, along with increased proliferation index is associated with disease progression from intramedullary to extramedullary sites in MM.
|
19201468 |
2009 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, CD56 expression carries no distinct adverse prognosis and the lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM.
|
18231917 |
2008 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, our results indicate that lack of CD56 expression on MM cells is not a prognostic marker in patients treated with high-dose chemotherapy, but is associated with t(11;14).
|
17891186 |
2007 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Standard MoAb panel for ALL and triple labeled antibodies (CD38/CD56/CD19) and detection of intracellular light chains for MM were used.
|
15739024 |
2005 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We also report that CD56-negative MM is the unique entity characterized by poor prognosis with high incidence of extramedullary disease, Bence Jones protein, renal insufficiency, thrombocytopenia and plasmablastic morphology.
|
15061198 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the MM samples 78% were CD56+ in smears and 92% positive in biopsies.
|
15049904 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM.
|
14531906 |
2003 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In B cell lines and flowsorted CD38++/CD19-/CD56++ myeloma plasma cells (N = 14) the c-maf/GAPDH and IL-4/GAPDH ratios were determined simultaneously using real time RT-PCR.
|
14692531 |
2003 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report on the different expression of CD56 and CD44 in plasma cells (PCs) simultaneously collected from bone marrow, extramedullary locations and peripheral blood in seven patients with multiple myeloma.
|
11841427 |
2002 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma expressing CD19(+)CD56(-) phenotype.
|
10911386 |
2000 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunophenotypic expression was similar for CD38, CD138, CD2, CD3, CD16, CD10, CD13, and CD15, but PCL differed from MM in the expression of CD56, CD9 HLA-DR, CD117, and CD20 antigens.
|
9920853 |
1999 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparing the ratio of diploid to DNA aneuploid with that of CD56+ to CD56- plasma cells, a correlation was found in MGUS (r = 0.7320) in the early stages of MM, I and II (r = 0.8023), but not in stage III MM.
|
9583896 |
1998 |